PulmoSIM wins U.S. patent allowance for lead inhaled therapy PT001

PulmoSIM Therapeutics secured a U.S. Notice of Allowance for a patent covering its lead candidate PT001, strengthening intellectual property around the inhaled therapy and backing VeriSIM Life’s AI-enabled drug development platform. The milestone comes as the company advances PT001 toward first-in-human studies in pulmonary hypertension and related lung diseases.

Why it matters: - The patent allowance gives PulmoSIM Therapeutics foundational U.S. protection around PT001, its lead inhaled drug candidate. - The decision strengthens the company’s intellectual property position as PT001 moves toward first-in-human studies. - The milestone also supports VeriSIM Life’s broader strategy of pairing a commercial AI platform with internally developed therapeutics.

What happened: - The U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 18/025,563. - The application is titled “Compositions and Methods for Treating or Preventing Pulmonary Hypertension.” - PulmoSIM Therapeutics announced the allowance on Aug. 12, 2026. - PulmoSIM Therapeutics is a wholly owned subsidiary of VeriSIM Life.

The details: - The allowance confirms the USPTO completed substantive examination and found the application meets patentability requirements. - The patent supports PT001 and complements additional pending applications covering pulmonary fibrosis, dry powder inhalation formulations and related therapeutic innovations. - PT001 is a first-in-class inhaled small molecule designed to increase drug exposure in the lungs while limiting systemic exposure. - The program is being developed for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease and other pulmonary diseases with significant unmet medical need. - In multiple preclinical studies, PT001 has shown improvements in pulmonary vascular remodeling, pulmonary vascular resistance, right ventricular function and biomarkers tied to disease progression. - PT001 has also reversed established fibrosis in pulmonary fibrosis models. - VeriSIM Life says PT001 was designed and advanced using BIOiSIM, its platform that combines mechanistic biosimulation with explainable artificial intelligence. - BIOiSIM is intended to predict pharmacokinetics, efficacy, safety and human clinical translation.

Between the lines: - The patent allowance does more than protect one drug candidate. It helps validate the company’s approach to using computational tools to build proprietary therapeutic assets. - The combination of IP, AI and preclinical data is meant to reduce development uncertainty before clinical testing. - PulmoSIM and VeriSIM are positioning PT001 as proof that mechanistic biology plus AI can speed translation from discovery to clinic. - The companies are also signaling that their business model depends on creating both medicines and platform value, which could support future partnerships.

What's next: - PulmoSIM said PT001 is moving toward first-in-human studies. - The company will continue advancing its pulmonary disease pipeline, including programs for pulmonary fibrosis and related inhaled formulations. - VeriSIM Life plans to keep using BIOiSIM to generate and optimize therapeutic assets.

The bottom line: - PulmoSIM gained a key U.S. patent step for PT001 just as it pushes the inhaled therapy closer to clinical testing, giving the company stronger protection and more leverage for its AI-driven drug development story.